Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

cath lab stents bioresorbable amaranth fortitude scaffold
Feature
January 14, 2014 — Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp. The ...
Home January 14, 2014
Home
ACC, iPad cardiology apps
Feature | Dave Fornell
DAIC readers chose the following stories as the most popular content in 2013, based on website analytics. The list is ...
Home January 03, 2014
Home
stents bioresorbable cath lab intravascular imaging clinical trial study abbott
Feature
November 7, 2013 — The Cardiovascular Research Foundation (CRF) and the Uppsala Clinical Research Center (UCR) of ...
Home November 07, 2013
Home
Feature
November 1, 2013 — A study found that both drug-eluting stents (DES) with biocompatible polymers and DES with ...
Home November 01, 2013
Home
News
October 31, 2013 — Amaranth Medical presented positive six-month angiographic results from its first-in-human study of ...
Home October 31, 2013
Home
News

October 23, 2013 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to ...

Home October 23, 2013
Home
News

October 8, 2013 — Micell Technologies Inc. announced that a peer reviewed article discussing imaging and clinical ...

Home October 08, 2013
Home
News

September 20, 2013— The Mount Sinai Medical Center is participating in the nationwide Absorb III clinical trial testing ...

Home September 20, 2013
Home
Technology

July 12, 2013 — Micell Technologies Inc. received CE mark approval for its MiStent sirolimus-eluting absorbable polymer ...

Home July 12, 2013
Home
News

June 24, 2013 — Final six and 12-month results of the DIRECT first-in-man clinical study were presented by study ...

Home June 24, 2013
Home
Elixer bioresorbable stent
Feature

May 16, 2013 — Elixir Medical Corp. announced it received CE (Conformité Européenne) mark approval for its DESolve ...

Home May 16, 2013
Home
bioresorbable stent, zinc stent
Feature

May 15, 2013 — In 2012, more than 3 million people had stents inserted in their coronary arteries. After about six ...

Home May 16, 2013
Home
News

April 2, 2013 — Reva Medical Inc. announced that it has initiated patient enrollment into a clinical trial with its ...

Home April 02, 2013
Home
News

March 20, 2013 — Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct Implantation ...

Home March 20, 2013
Home
News

March 15, 2013 — Abbott announced positive long-term results for the company's innovative Absorb Bioresorbable Vascular ...

Home March 15, 2013
Home
Subscribe Now